Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SIBP-03 injection plus cetuximab in recurrent/metastatic advanced head and neck squamous cell carcinoma (non-nasopharyngeal)
CTR20234099Phase 2Active
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of SIBP-03, cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Institute of Biological Products. Started Sep 2024; status: active.
02
Drugs
SIBP-03cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20234099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234099.